Lensar, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 07:30 am
Share
LENSAR, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 7.922 million compared to USD 5.047 million a year ago. Operating loss was USD 4.375 million compared to USD 3.843 million a year ago. Net loss was USD 4.362 million compared to USD 4.497 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 4.2 a year ago. For the half year, total revenue was USD 14.965 million compared to USD 10.953 million a year ago. Operating loss was USD 9.575 million compared to USD 6.942 million a year ago. Net loss was USD 9.544 million compared to USD 8.183 million a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 7.65 a year ago.
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
LENSAR, INC. 
